PF-Atlas › Clinical Trials › NCT00056147

Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease

denufosol tetrasodium · Phase 2

Registry ID
NCT00056147
Phase
Phase 2
Status
Completed
Drug / intervention
denufosol tetrasodium (INS37217)
Sponsor
Merck Sharp & Dohme LLC
Start
2003-04
Enrollment
90

About this trial

The purpose of this study is to assess the safety and effectiveness of multiple dosages of INS37217 compared to placebo over 28 days in subjects with mild to moderate cystic fibrosis (CF) lung disease. Study drug will be administered through a nebulizer (a device that delivers medication as a mist by breathing it in).

View NCT00056147 on ClinicalTrials.gov →

Explore related

All denufosol tetrasodium trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT00056147 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.